PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

CGT CDMO Partnering: More than just Manufacturing

The biotech footprint has been exponentially expanding around the globe and no division has increased more feverishly in recent years than the Cell and Gene Therapy (CGT) space. This is where partnering with an experienced CDMO can de-risk your path to said critical milestones and provide that seamless transition from development to the clinic and into both a regional and global commercial supply. Joe Garrity at Lonza Cell and Gene Technologies outlines the importance of partnering with an experienced CDMO.

Extract:

CGT CDMO Partnering: More than just Manufacturing

The biotech footprint has been exponentially expanding around the globe and no division has increased more feverishly in recent years than the Cell and Gene Therapy (CGT) space. With hundreds to thousands of products in the pre-clinical and clinical phases, the industry has improved in both a quantitative and qualitative way, but it has also exposed numerous pain points that have created critical bottlenecks affecting the ability for a smooth transition into clinic and subsequently to market. With the CGT space being at a critical inflection point, the current ways of working to develop, manufacture, and deliver products and treatments to customers (and subsequent patients) results in a greater need to access GMP manufacturing capacity for meeting clinical and commercial demand, particularly for small biotech firms developing cell and gene therapies. With continuing pressure coming from accelerated timelines and milestone deliveries without sacrificing quality, many of these firms lack the expertise, facilities, and supply networks needed to quickly scale up for clinical or commercial development. This is where partnering with an experienced CDMO can de-risk your path to said critical milestones and provide that seamless transition from development to clinic and into both a regional and global commercial supply.

While the cell therapy and gene therapy field has been around in some way, shape, or form since the 1950s and 1970s respectively, only in recent years has the industry really started to take off. Over those previous decades of predominately research and development, the landscape has morphed from viral vector to allogeneic to autologous and everywhere in between. Today’s landscape is a healthy mix of all three modalities and is expected to continue as such as depicted in Table 1 (as shown in the downloaded PDF).

Click the download button below to read the complete version of ‘CGT CDMO Partnering: More than just Manufacturing’ by Joe Garrity at Lonza Cell and Gene Technologies 

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40